Skip to main content
. 2020 Mar 12;5(5):e132158. doi: 10.1172/jci.insight.132158

Figure 1. Decreased hepatic fibrosis in carriers of the HSD17B13 rs72613567 variant.

Figure 1

(A) The percentage of subjects with steatosis (macrovesicular steatosis, ≥5%). (B) The percentage of subjects with necroinflammatory activity (activity grade, ≥1). (C) The percentage of subjects with fibrosis (fibrosis stage, ≥1) in the TT (n = 118) and TTA/TATA (n = 84) groups, as determined histologically using the SAF score. Distributions were tested using Pearson’s χ2 test. Black bars = TT; green bars = TTA/TATA. *P < 0.05.